GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » Forward Dividend Yield %

IRLAB Therapeutics AB (OSTO:IRLAB A) Forward Dividend Yield % : 0.00% (As of Sep. 22, 2024)


View and export this data going back to 2017. Start your Free Trial

What is IRLAB Therapeutics AB Forward Dividend Yield %?

As of today (2024-09-22), the Forward Annual Dividend Yield of IRLAB Therapeutics AB is 0.00%.

As of today (2024-09-22), the Trailing Annual Dividend Yield of IRLAB Therapeutics AB is 0.00%.

OSTO:IRLAB A's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.59
* Ranked among companies with meaningful Forward Dividend Yield % only.

IRLAB Therapeutics AB's Dividends per Share for the three months ended in Jun. 2024 was kr0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of IRLAB Therapeutics AB's Forward Dividend Yield %

For the Biotechnology subindustry, IRLAB Therapeutics AB's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IRLAB Therapeutics AB's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where IRLAB Therapeutics AB's Forward Dividend Yield % falls into.



IRLAB Therapeutics AB Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


IRLAB Therapeutics AB  (OSTO:IRLAB A) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


IRLAB Therapeutics AB Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of IRLAB Therapeutics AB's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


IRLAB Therapeutics AB Business Description

Traded in Other Exchanges
Address
Arvid Wallgren Backe 20, Goteborg, SWE, 413 46
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB Headlines

No Headlines